Calcitonin as an adjunct for phantom limb pain
PLOS One · 16.06.2026 · 21 (6) · e0351739
DOI: 10.1371/journal.pone.0351739 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 16.06.2026. Verfasst von Sneha Vidyasagar und 3 weiteren Autor:innen. Beteiligte Einrichtung: Logan Endocrine and Diabetes Service, Logan, QLD, Australia. Hauptthemen laut MEDLINE: Phantom Limb, Calcitonin. Die Arbeit nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
This retrospective study evaluated calcitonin as an adjunct therapy for reducing phantom limb pain (PLP) following lower limb amputation.
Method
The study included 35 patients who received at least 3 days of calcitonin treatment between January 1, 2017, and December 31, 2023. We collected demographic data and pain ratings (intensity, distress, and interference with activity) before and after calcitonin treatment. Descriptive statistics and paired t-tests analysed the data, with a two-way repeated measures ANOVA used to compare outcomes between patients with and without diabetes. Raw and Standardized mean differences (Cohen’s d) are presented for each measure.
Results
The average age of participants was 57.09 years (SD = 13.66), with 40% female. Amputation types were below-knee (65.7%), above-knee (25.7%), and other (8.6%). The main causes of amputation included diabetic foot infection (25.7%), peripheral vascular disease (34.3%), trauma (25.7%), and other (14.3%). Ten participants had diabetes, and 20% had depression. Calcitonin was associated with significant reductions in pain outcomes from pre- to post-intervention (Day 0 to Day 7), with calcitonin given from day 1–3. Mean pain intensity decreased from 6.41 to 5.24 (Cohen’s d = 0.66); p = 0.02), and pain-related distress decreased from 5.85 to 4.81 (Cohen’s d = 0.71; p = 0.014). Perceived pain relief scores increased from 33.69 to 58.21, indicating greater patient-reported pain relief following treatment (Cohen’s d = 0.53; p = 0.035). No significant differences in pain intensity or distress were observed between patients with and without diabetes. Additionally, there was no significant change in the Oral Morphine Equivalent Daily Dose (p = 0.94).
Conclusion
In conclusion, calcitonin significantly reduced perceived pain intensity and pain-related distress scores while increasing perceived pain relief scores (i.e., patients’ reported degree of pain reduction), with similar effects observed in both patients with and without diabetes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Logan Endocrine and Diabetes Service, Logan, QLD, Australia.
- Department of Diabetes and Endocrinology, Princess Alexandra Hospital, Brisbane, QLD, Australia.
- QCIF Biostatistics, Brisbane, QLD, Australia.
- Department of Geriatric Medicine, Princess Alexandra Hospital, Brisbane, QLD, Australia.
- The University of Queensland School of Medicine, Brisbane, QLD, Australia.
ORCID-Profile: Sneha Vidyasagar
Zitieren
APA
Vidyasagar, S., Jeyaraman, K., Zahir, S. F., & Varghese, P. (2026). Calcitonin as an adjunct for phantom limb pain. PLOS One, 21(6), e0351739. https://doi.org/10.1371/journal.pone.0351739
Vancouver
Vidyasagar S, Jeyaraman K, Zahir SF, Varghese P. Calcitonin as an adjunct for phantom limb pain. PLOS One. 2026;21(6):e0351739. doi:10.1371/journal.pone.0351739
BibTeX
@article{Vidyasagar2026,
author = {Vidyasagar, Sneha and Jeyaraman, Kanakamani and Zahir, Syeda Farah and Varghese, Paul},
title = {Calcitonin as an adjunct for phantom limb pain},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {6},
pages = {e0351739},
doi = {10.1371/journal.pone.0351739}
}
EUVIMED